Bone marrow transplantation for XXXX .

@entity1 @entity295 @entity2150 @entity786 @entity205 @entity281 @entity2132 @entity1499 @entity204
Fifteen @entity1 (nine male, six female) with @entity2150 ( @entity2150 ) undergoing HLA-identical allogeneic bone marrow transplantation (BMT) received preparative regimens consisting of @entity786 and total lymphoid irradiation. @entity1 were aged from eight to 26 years (median 15 years). Prophylaxis of @entity2132 ( @entity2132 ) including @entity205 and short course @entity1499 was administered. One @entity204 occurred at day 8 post BMT. Among the other 14 @entity1 , one died of @entity295 at day 53 with no evidence of engraftment, 13 were engrafted despite the number of donors exposed in transfusions of previous blood components. Eleven @entity1 have survived from six to 100 months (median, 54 months), post BMT. The remaining two @entity1 died of @entity2132 on days 44 and 63. Acute @entity2132 occurred among eight of 13 engrafted @entity1 , five of whom were grades II-IV clinically. @entity2132 developed among five @entity1 , three of whom were clinically progressive and extensive. Two of three @entity1 with extensive @entity2132 had received transfusion of donor's buffy coat after BMT. Our data indicate an engraftment rate of 87% (13/15). The projected probability of disease-free survival was 73% (11/15) at 9.3 years after BMT according to the Kaplan-Meier model. Further efforts must be made to eliminate @entity2132 and to control fatal @entity281 .
